PropertyValue
?:definition
  • A synthetic peptide-based, personalized cancer vaccine consisting of multiple patient-specific tumor peptides, which are immunogenic and unique to the patient\'s tumor, combined with the immunostimulant polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), with potential immunomodulating and antineoplastic activities. Upon vaccination with the personalized genomic vaccine 001 (PGV001), the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant Poly-ICLC is added to boost the immune response to the peptides and together will expand immune cells to target cancer. The adjuvant poly-ICLC is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens. Check for \'https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C136466\' active clinical trials using this agent. (\'http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C136466\' NCI Thesaurus)
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
expand all